People · Operator
Named in public records as an officer, director or promoter · active 2015–2025 · Other Health Care, Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Rallybio Holdings, LLC | — | Other Health Care | Series D+ | $157.8M | $69.6M | 2024 |
| Iterum Therapeutics Ltd | — | Biotechnology | Series C | $131.4M | $115.9M | 2015 |
| Iterum Therapeutics Bermuda Ltd | — | Pharmaceuticals | Series C | $51.6M | $1.8B | 2020 |
| Qlaris Bio, Inc. | — | Biotechnology | Series B | $37.8M | $22.4M | 2024 |
Ronald M. Hunt at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ronald M. Hunt on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James I. Healy | 2 | 7 |
| Patrick J. Heron | 2 | 7 |
| Ron Hunt | 2 | 4 |
| David M Kelly | 2 | 3 |
| Brenton K. Ahrens | 2 | 3 |
| Shahzad M. Malik | 2 | 3 |
| Judith M. Matthews | 2 | 2 |
| Michael M. Dunne | 2 | 2 |
| Louise M. Barrett | 2 | 2 |
| Corey N. Fishman | 2 | 2 |
| Mark I. Chin | 2 | 2 |
| Wende Hutton | 1 | 16 |
| Ketan Patel | 1 | 10 |
| Kush Parmar | 1 | 10 |
| Tim Shannon | 1 | 9 |
| Adrienne Graves | 1 | 6 |
| Robert Hopfner | 1 | 3 |
| Patrick N. Heron | 1 | 3 |
| Andrew Danielsen | 1 | 3 |
| KUSH M. PARMAR | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.